Literature DB >> 12670813

Prophylactic ip injection of bupivacaine and/or morphine does not improve postoperative analgesia after laparoscopic gynecologic surgery.

Hawa Keita1, Jean Louis Benifla, Violaine Le Bouar, Raphaël Porcher, Bogena Wachowska, Karima Bedairia, Jean Mantz, Jean Marie Desmonts.   

Abstract

PURPOSE: To determine the effectiveness of ip bupivacaine and/or morphine for postoperative analgesia after laparoscopic surgery. A controversy exists on the effectiveness and clinical value of ip injection of local anesthetics for postoperative analgesia. A possible peripheral analgesic effect of morphine after ip injection remains debated as well.
METHODS: We conducted a randomized, double-blinded, study to compare the efficacy of prophylactic ip administration of 0.9% saline (n = 16), 0.5% bupivacaine (100 mg, n = 15), morphine (3 mg, n = 16) and a mixture with 0.5% bupivacaine (100 mg) and morphine (3 mg, n = 18) to reduce both postoperative pain scores and analgesic requirements after gynecologic laparoscopic surgery. A multimodal analgesia regimen (acetaminophen, nonsteroidal anti-inflammatory drugs and morphine) was used for postoperative analgesia.
RESULTS: No difference was observed in postoperative pain scores (visual analogue scale at rest and on coughing), or analgesic requirements during the first 24 postoperative hours between the four groups. There was also no significant intergroup difference in sedation scores and incidence of nausea and vomiting.
CONCLUSION: When multimodal postoperative analgesia is used, prophylactic ip administration of 100 mg bupivacaine and/or 3 mg morphine does not significantly improve postoperative analgesia in patients undergoing laparoscopic gynecologic surgery.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12670813     DOI: 10.1007/BF03021033

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  7 in total

Review 1.  Better late than never? Impact of local analgesia timing on postoperative pain in laparoscopic surgery: a systematic review and metaanalysis.

Authors:  Shaun M Coughlin; Paul J Karanicolas; Heather M A Emmerton-Coughlin; Bilge Kanbur; Savas Kanbur; Patrick H D Colquhoun
Journal:  Surg Endosc       Date:  2010-05-20       Impact factor: 4.584

Review 2.  Peripheral opioid analgesia: clinical applications.

Authors:  Jochen Oeltjenbruns; Michael Schäfer
Journal:  Curr Pain Headache Rep       Date:  2005-02

3.  A double-blinded randomised controlled study to investigate the effect of intraperitoneal levobupivacaine on post laparoscopic pain.

Authors:  T K Cunningham; H Draper; H Bexhell; V Allgar; J Allen; D Mikl; K Phillips
Journal:  Facts Views Vis Obgyn       Date:  2020-10-08

4.  Continuous infusion of intraperitoneal bupivacaine after laparoscopic surgery: a randomized controlled trial.

Authors:  Danny A Sherwinter; Amir M Ghaznavi; David Spinner; Richard H Savel; Jerzy M Macura; Harry Adler
Journal:  Obes Surg       Date:  2008-07-22       Impact factor: 4.129

5.  Interventions to reduce shoulder pain following gynaecological laparoscopic procedures.

Authors:  Philip Kaloo; Sarah Armstrong; Claire Kaloo; Vanessa Jordan
Journal:  Cochrane Database Syst Rev       Date:  2019-01-30

6.  Guidelines for postoperative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations--Part II.

Authors:  G Nelson; A D Altman; A Nick; L A Meyer; P T Ramirez; C Achtari; J Antrobus; J Huang; M Scott; L Wijk; N Acheson; O Ljungqvist; S C Dowdy
Journal:  Gynecol Oncol       Date:  2016-01-03       Impact factor: 5.482

Review 7.  A Systematic Review and Meta-Analysis of Intraperitoneal Bupivacaine in Laparoscopic Gynecologic Surgery.

Authors:  Greg Marchand; Kelly Ware; Malini Govindan; Ahmed T Masoud; Alexa King; Stacy Ruther; Giovanna Brazil; Kaitlynne Cieminski; Nicolas Calteux; Catherine Coriell; Hollie Ulibarri; Julia Parise; Amanda Arroyo; Diana Chen; Maria Pierson; Rasa Rafie; Katelyn Sainz
Journal:  J Pain Res       Date:  2021-09-02       Impact factor: 3.133

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.